Urolithin A Capsules Manufacturer

OEM and private label Urolithin A capsules. Custom dosage, capsule format, formulation, testing, packaging and production support.

Request Formula Consultation

What KS Nutripharma Delivers for Urolithin A Capsule Projects

Manufacturing Model	OEM · ODM · Private Label
Dosage Form	Hard capsules (HPMC or gelatin shell)
Dose Range	250 mg – 1000 mg active per serving, subject to formula feasibility
Capsule Sizes	#1 · #0 · #00, confirmed after fill-weight assessment
Formula Types	Single-ingredient or multi-ingredient (e.g., CoQ10, PQQ)
Raw Material Check	Identity, assay, bulk density, flowability, moisture, contaminants
Release Testing	Identity, assay, weight variation, disintegration, microbiological
Documentation	COA, specification sheet, test methods, regulatory docs per market
Production Scale	Pilot batch → commercial volume
Typical Lead Time	4–6 weeks after formula and artwork confirmation
MOQ	Available upon project review

Before any commercial batch, we run a trial blend to confirm fill weight, powder flow and capsule size feasibility.

Request a Manufacturing Quote

Factory Overview:

Metric	What It Means for Your Project
19+	Years in supplement manufacturing
81,000 m²	Total manufacturing footprint
5	Production bases
500+	Brands served globally
60+	Export markets
cGMP/ISO/HACCP/FSSC 22000/HALAL/KOSHER	Certifications held

Urolithin A Capsule Dosage Options

These are manufacturing dosage options, not health recommendations.

Target Active per Serving	Typical Capsule Format	Manufacturing Considerations
250 mg	1 capsule	Lower fill requirement; fits #0 or #1
500 mg	1–2 capsules	Common high-dose target; #0 typical starting point
1000 mg	2 capsules or custom config	Fill weight and serving size require feasibility review
Custom	Based on specification	Formula review required for assay, excipients and fill weight

Work Process-From Raw Material to Finished Capsule

Urolithin A Formula & Capsule Configuration

Urolithin A capsule configuration starts with the actual raw material specification, not the target active dose alone.

Ready-to-Adapt Urolithin A Capsule Formula Concepts

Urolithin A capsules can be developed as single-ingredient products or combined with established actives used across healthy aging, mitochondrial wellness, longevity and active-aging categories.

The following are reference formulation concepts for commercial product development. Dosages can be adjusted according to raw material specifications, capsule capacity, target market, product positioning and cost requirements.

09. Urolithin A + Alpha-Lipoic Acid

Suggested Formula
Urolithin A · 250–500 mg + Alpha-Lipoic Acid · 100–300 mg

Product Positioning
A mitochondrial and antioxidant-oriented formula for brands seeking a more established nutraceutical ingredient alongside Urolithin A.

Best For

Healthy-aging products
Mitochondrial wellness
Antioxidant-focused formulas
Science-oriented supplement brands

Why It Works
Alpha-lipoic acid creates a different formulation direction from the NMN and longevity combinations while remaining relevant to the broader healthy-aging category.

Formulation Consideration
Raw material stability, assay, particle characteristics and packaging requirements should be evaluated during product development.

Send Inquiry Now

« Previous 1 2 3 4

Stability & Packaging for Urolithin A Capsules

Urolithin A capsule stability was evaluated at the finished-product level. Packaging selection depends on the complete formulation, raw material characteristics, moisture exposure, storage conditions, target shelf life, and required barrier performance—not on the urolithin A ingredient alone.

How We Evaluate

Factor	Assessment
Moisture exposure	Finished blend sensitivity; whether additional moisture protection is needed
Temperature & storage	Target market, transportation and recommended storage conditions
Light & oxygen	Relevant to formulation and packaging specification
Excipient compatibility	Complete formulation evaluated, not Urolithin A in isolation
Target shelf life	Determines stability evidence and packaging performance required

Packaging Options

HDPE Bottle Standard solid-dose option. Protection level depends on the complete container-closure configuration, not simply the bottle material.

HDPE Bottle + Desiccant Considered when additional moisture control is appropriate for the finished formulation. Desiccant type and quantity are selected according to bottle configuration, product fill and expected storage environment—not automatically added to every product.

Blister Packaging Unit-dose protection and portability. Actual moisture, oxygen and light barrier performance depends on the selected blister structure and material specification.

High-Barrier Packaging Considered when the finished product requires greater environmental protection or when distribution conditions demand it. Selected based on identified stability requirements rather than as a marketing upgrade.

Stability Evaluation

Finished-product stability testing in the intended packaging configuration is used where required. Evaluation may include:

Urolithin A assay
Appearance and physical characteristics
Moisture-related parameters
Microbiological quality
Packaging compatibility

Long-term and/or accelerated studies support the shelf-life specification. Packaging alone does not establish shelf life.

How We Determine Final Packaging

Formula & Raw Material Specification
            ↓
Moisture / Environmental Risk Assessment
            ↓
    Packaging Configuration
            ↓
Finished-Product Stability Evaluation
            ↓
    Shelf-Life Specification

This ensures packaging is matched to the actual formula, target market and storage requirements.

Research & Regulatory Considerations

Urolithin A has been studied in human and preclinical research, but the strength of evidence varies by outcome. For B2B product development, research findings should be distinguished from permitted product claims and market-specific regulatory requirements.

What Human Research Has Examined

Human studies have evaluated Urolithin A in areas including:

Safety and tolerability
Pharmacokinetics
Mitochondrial-related biomarkers
Muscle-related outcomes
Physical performance

These findings provide a scientific basis for product development, but research outcomes should not automatically be presented as proven clinical benefits. Mechanistic findings—including research involving mitochondrial function or mitophagy—should be distinguished from demonstrated clinical efficacy.

Research evidence does not automatically establish a disease-treatment, disease-prevention or therapeutic claim for a finished supplement product.

U.S. Regulatory Considerations

A specific Urolithin A ingredient received an FDA “no questions” response under GRAS Notice No. 791 for the uses and conditions described in that notice.

GRAS is not FDA approval.

The regulatory status described in a GRAS notice applies to the specific ingredient, specifications, intended uses and conditions covered by the notice. It should not be interpreted as blanket authorization for every Urolithin A ingredient, formulation, dosage or finished supplement product.

For a commercial product, regulatory review should consider:

Ingredient specification
Intended use
Finished-product formulation
Serving level
Product category
Label claims
Target market

EU Market Considerations

EU market entry requires a separate regulatory assessment. Depending on the ingredient specification, intended use and product configuration, novel-food status and applicable EU requirements may need to be evaluated before commercialization.

A regulatory conclusion for the U.S. market should not be assumed to apply automatically to the EU or other jurisdictions.

Product Claims & Compliance

The scientific literature can inform product development, but finished-product claims must be reviewed against the regulations of the intended market.

We distinguish between:

What has been studied

and

What can legally be claimed on a finished supplement label.

Final claims, labeling and regulatory positioning should be confirmed according to the target market and applicable requirements.

What Affects Your Manufacturing Cost & Lead Time?

Manufacturing cost and lead time depend on the final product specification, not Urolithin A dosage alone.

What Affects Manufacturing Cost?

Factor	How It Affects Your Project
Raw material specification	Assay affects the amount of raw material required. Commercial cost also depends on grade, supplier, purchasing volume and required documentation.
Formula complexity	Single-ingredient vs. multi-ingredient formulas can affect procurement, blending, testing and stability requirements.
Active dose & fill weight	Higher active loading increases raw material consumption and may increase capsule size or capsules per serving.
Capsule shell	HPMC and gelatin have different material costs and market-positioning implications.
Packaging	Stock formats can simplify procurement. Custom bottles, printed components or custom blister structures may require additional tooling, MOQs or approval steps.
Testing & documentation	Additional identity, assay, contaminant, microbiological, stability or market-specific testing may add cost and processing time.
Order volume	Affects raw material purchasing, packaging quantities, production efficiency and unit economics.

What Affects Lead Time?

Factor	Impact
Formula & specification confirmation	Incomplete formulas or changing specifications can delay development.
Raw material availability	Timing depends on whether the required Urolithin A grade and other ingredients are available in the required quantity.
Sample & trial development	Custom formulas may require trial blending and capsule-fill verification before commercial production.
Packaging & artwork	Custom packaging, artwork revisions and label approval can extend the project timeline.
Testing & release	Required finished-product testing must be completed before batch release.
Production scheduling	Commercial production timing depends on batch requirements, production capacity and the confirmed manufacturing schedule.

Typical Commercial Timeline

Project & Specification Review
↓
Formula & Raw Material Confirmation
↓
Sample / Trial Development — if required
↓
Packaging & Artwork Approval
↓
Commercial Production
↓
Finished Product Testing & Release

Typical commercial lead time is approximately 4–6 weeks after formula, specifications, packaging and artwork are confirmed, subject to raw material availability, testing requirements and production scheduling.

Request a Urolithin A Capsule Manufacturing Quote

Send us your target Urolithin A dose, formula concept, order quantity, packaging requirements and target market.

Our team will review the formulation and capsule configuration, identify any key manufacturing considerations and prepare a project quotation based on the confirmed specification.

Information to Include

Product Specification

Target Urolithin A dosage
Capsules per serving
Single-ingredient or multi-ingredient formula
HPMC / gelatin / undecided

Formula & Technical Requirements

Existing formula or formulation support required
Capsule size — if known
Existing raw material specification or COA — if available
Special testing or documentation requirements

Commercial Requirements

Target order quantity
Packaging format
Target market / sales region
Desired launch timeline, if applicable

Don’t Have a Finalized Formula?

That’s fine.

You can start with the information you already have, such as:

500 mg Urolithin A + capsules + 10,000 bottles + U.S. market

We can then review the formula feasibility, capsule configuration, testing requirements and packaging options before finalizing the manufacturing quotation.

What Urolithin A dosage can you manufacture in capsules?

Custom dosages are feasible based on formula review. Common manufacturing targets include 250 mg, 500 mg and 1000 mg active per serving, subject to raw material assay and capsule fill-weight capacity.

Can you manufacture 500 mg or 1000 mg Urolithin A capsules?

Yes. 500 mg is a common manufacturing target, typically using #0 capsules. 1000 mg may require multiple capsules or #00, confirmed after fill-weight feasibility assessment.

Can Urolithin A be combined with CoQ10, PQQ or other actives?

Yes. Multi-ingredient formulas are supported, subject to compatibility and stability assessment during formula development.

What Urolithin A testing and documentation can you provide?

We provide COA, specification sheets, test methods, allergen statements, GMO statements and other agreed documents. Finished-product testing includes identity, assay, weight variation, disintegration and microbiological testing per the approved specification.

How do you determine capsule size and fill weight?

Capsule size is determined by total fill weight, which depends on active dose, raw material assay, excipients and bulk density. We confirm this through trial blending before production.

What affects MOQ and manufacturing lead time?

MOQ depends on formula complexity, packaging type and order volume. Lead time is typically 4–6 weeks after formula and artwork confirmation, subject to raw material availability and testing requirements.

What information do you need to quote a Urolithin A capsule project?

Target dose, capsule type, serving size, formula requirements, target quantity, packaging format, target market, and whether you need formulation support.

Get an Instant Quote Now